Capital Flow Monitor · Sponsors · CIK 2138046
ARCH Venture Fund XIV, L.P.
8755 W. Higgins Road, Suite 1025, Chicago, IL, 60631 · 773-380-6600
Pooled Investment Fund / Venture Capital Fund · Limited Partnership· inc. DELAWARE true 2026
Fit score
—
Offering
$3.0B
Sold
$0
% sold
0.0%
Investors
0
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-08-31 | D ·current | 506(b) | $3.0B | $0 | 0.0% | 0 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- N/A ARCH Venture Partners XIV, L.P. — Director, Chicago, IL
- N/A ARCH Venture Partners XIV, LLC — Director, Chicago, IL
-
Kristina Burow — Executive Officer, Chicago, IL
1 other raise
- Treeline Biosciences, Inc. $200.1M of $250.0M · 80.0%
- Keith L. Crandell — Executive Officer, Chicago, IL
- Jason Doren — Executive Officer, Chicago, IL
-
Steven Gillis — Executive Officer, Chicago, IL
2 other raises
- SonoThera, Inc. $125.5M of $125.5M · 100.0%
- Pheast Therapeutics, Inc. $24.6M of $40.0M · 61.5%
- Mark McDonnell — Executive Officer, Chicago, IL
- Robert T. Nelsen — Executive Officer, Chicago, IL
-
Paul Berns — Executive Officer, Chicago, IL
1 other raise
- Ollin Biosciences, Inc. $156.2M of $330.0M · 47.3%
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.